November 18, 2019 | NBC News

NIH Experiments With Drug to Reduce Opioid Cravings

The National Institutes of Health in Bethesda, Maryland, is testing an experimental drug that could save lives in the fight against the opioid epidemic.

October 17, 2019 | Amygdala Press Release

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including…

March 21, 2019 | NIH Press Release

NIH to Test Experimental Drug to Curb Opioid Cravings

A clinical trial of an experimental drug designed to treat cravings associated with opioid use disorder (OUD) has begun in the National Institutes of Health Clinical Center.

February 16, 2017 | Amygdala Press Release

Amygdala Neurosciences Acquires GS-6637 from Gilead